If you have been searching for retatrutide and keep landing on pages that feel like they are selling you something, that frustration makes sense. This is an independent guide. It does not sell retatrutide and it is not affiliated with Eli Lilly. It explains what retatrutide actually is, where it stands legally and medically, and what the telehealth referral link on this page leads to.
Independent educational guide. Not affiliated with Eli Lilly. Does not sell retatrutide.
Affiliate link: we may earn a referral fee if you proceed through the intake.
At a Glance
Topic
Retatrutide
Current Status
Investigational (Phase 3 trials)
Format Discussed
Once-weekly injection
Page Type
Independent editorial review
CTA Destination
Telehealth intake page
Availability Note
State-based eligibility may apply
Retatrutide is an investigational once-weekly injectable drug being studied for weight management and metabolic health, currently in Phase 3 clinical trials developed by Eli Lilly.
What separates it from most drugs in this category is the mechanism. Most existing weight-management injectables target one or two hormonal pathways. Retatrutide targets three: GLP-1, GIP, and glucagon. That triple-receptor approach is what has drawn significant attention from researchers watching the trial data.
It is not available as a standard retail product. You cannot simply order it like a supplement. Any website that implies otherwise is either misrepresenting what they are selling or operating in a legally and medically risky area.
This site does not sell retatrutide. For a deeper explanation, see our guide on what retatrutide is.
No. Retatrutide is not FDA approved as of 2026. It is still in Phase 3 clinical trials. That distinction matters enormously when evaluating anything you find online about it.
Any website that implies you can simply purchase retatrutide as a normal consumer product is either describing something different, misrepresenting what they are selling, or operating in a space that carries serious legal and health risk. Investigational drugs are not the same as approved medications.
If you see a site that calls retatrutide "available now" without explaining its investigational status, treat that as a warning sign. For a full breakdown, see our retatrutide FDA approval status page.
This site is an independent editorial review and referral resource. It was built to help people who are researching retatrutide understand what it is before they make any decisions.
Affiliate disclosure: the referral link on this page connects to a third-party telehealth intake platform. If you proceed through that process, this site may earn a referral fee at no extra cost to you. This site does not control what happens after you click.
To be explicit: this site is not affiliated with Eli Lilly. It is not the official retatrutide website. It does not sell retatrutide. Eli Lilly does not operate this page.
The affiliate link connects to a clinician-led intake flow, not a checkout page. See our full affiliate disclosure for more detail.
The referral link connects you to a telehealth intake form, not a product checkout. Here is what that typically involves:
Submit your state and basic details to confirm telehealth services are available in your area.
Complete a health intake form. A licensed clinician reviews your information.
If eligible, the clinician discusses clinician-led weight management options available to you.
Nothing is automatic. Continuing is your choice at every stage of the process.
State availability may vary. See our page on how telehealth intake works.
Retatrutide works by activating three hormone receptors at once. To understand why that matters, it helps to know what each one does.
GLP-1 (glucagon-like peptide-1) slows digestion and reduces appetite. It is the same pathway targeted by drugs like semaglutide and tirzepatide.
GIP (glucose-dependent insulinotropic polypeptide) supports insulin response and appears to play a role in fat storage and metabolism.
Glucagon raises blood sugar and increases energy expenditure by encouraging the body to burn stored fat, adding a third dimension to the mechanism.
Combining all three in a single weekly injection is the core of what retatrutide does differently. Trial data has shown significant weight reduction in participants. But trial data is not the same as approved outcomes. Do not read the trial numbers as a purchase pitch.
Anyone with a history of thyroid cancer or multiple endocrine neoplasia should not consider retatrutide without speaking directly with a specialist first. People taking medications that affect blood sugar, appetite, or hormonal function need to think carefully about interactions. Retatrutide is not appropriate for use during pregnancy or while breastfeeding based on current available information. Anyone with a serious chronic condition, including heart disease, kidney disease, or liver conditions, should have a thorough clinical conversation before exploring any weight-management injectable. Self-diagnosis and self-prescription are genuinely dangerous here. A licensed clinician is not a box to check. They are the entire process.
Retatrutide's safety profile is still being established through clinical trials. That is a statement of where things actually stand, not a dismissal of the research.
The side effects reported in trials so far are broadly consistent with other GLP-1 class drugs:
Because retatrutide is still investigational, the full picture of who experiences which side effects, at what severity, and under what conditions is not complete. For more detail, see our retatrutide side effects page.
This is probably the most practically useful section on this page. Use this checklist when evaluating any site you land on:
Clear FDA Status DisclosureDoes the site clearly state that retatrutide is not FDA approved? If not, that is a problem.
Defined Offer TypeDoes the site clearly explain whether it is a referral, a direct sale, or a telehealth intake? Blurred lines are a red flag.
Affiliate Disclosure PresentIs the affiliate relationship stated openly? If not, the site may not be operating transparently.
No Official Brand ClaimsDoes the site claim to be official Eli Lilly? If yes, it is not telling the truth.
No Impossible PromisesAre specific outcome guarantees promised without sourcing? That is a significant warning sign.
Seller Identity Is ClearCan you identify who is actually selling or referring, with verifiable contact information?
For more, see our full retatrutide legitimacy checklist.
| Page Type | Approval Transparency | Offer Clarity | Clinician Process |
|---|---|---|---|
| This independent editorial guide | Clear | Referral only | Described accurately |
| Direct miracle-claim pages | Often missing | Checkout disguised as review | Usually none |
| Generic supplement funnels | Not applicable or false | Product sale framing | None |
| Clinician-led intake pages | Generally clear | Intake process described | Core of the offer |
For a structured breakdown, see our clinician-led weight management options page.
No. Retatrutide is not FDA approved as of 2026. It is in Phase 3 clinical trials. Any claim to the contrary is inaccurate. See our full FDA status page for detail.
Retatrutide is not available as a standard retail product. The referral link on this site connects to a telehealth intake process, not a product checkout. Whether clinician-supervised access is available to you depends on your location, health status, and eligibility.
No. This site does not sell retatrutide. It is an independent educational review and referral resource. Clicking the referral link starts a telehealth intake process run by a separate third-party platform.
No. This is not an official website. It has no affiliation with Eli Lilly, which develops retatrutide. Eli Lilly does not operate this page.
You are taken to a third-party telehealth intake form. You submit health information, the platform checks your eligibility by state, and a licensed clinician reviews your case. No purchase or commitment happens automatically at that stage.
Retatrutide is a real investigational drug being studied by Eli Lilly in Phase 3 clinical trials. It is not a scam. Some websites offering products they call retatrutide may be misrepresenting what they are selling. The molecule itself is real and being actively studied.
Yes. All investigational drugs carry risk, and retatrutide's full safety profile is still being established. Common side effects reported in trials include nausea, vomiting, and gastrointestinal discomfort. A clinician should be part of any evaluation. See our side effects page.
You complete an intake form with health and personal information. A licensed clinician reviews it. If you meet eligibility criteria and services are available in your state, the clinician will discuss options with you directly. You are not automatically enrolled in anything. See our telehealth intake guide.
Yes. Telehealth services vary by state. The intake platform will confirm availability when you submit your information. Not all locations qualify.
A product checkout sells you something directly. A telehealth intake collects health information so a clinician can determine whether any option is appropriate for you. One is a transaction. The other is a medical screening process.
No. This site has no affiliation with Eli Lilly and does not represent the company in any capacity. Eli Lilly has no involvement in this page or its content.
Look for clear disclosure of affiliate relationships, an honest statement of FDA approval status, a described clinician process rather than a simple checkout, and no claims of being an official brand site. See our full legitimacy checklist.
GLP-1 is a hormone that slows digestion and reduces appetite. It is one of three receptors that retatrutide targets. The others are GIP and glucagon. Targeting all three at once in a single weekly injection is what makes retatrutide mechanistically different from most existing weight-management drugs.
No. Semaglutide targets GLP-1 only. Tirzepatide targets GLP-1 and GIP. Retatrutide targets all three: GLP-1, GIP, and glucagon. It is a different molecule at a different and earlier stage of development.
People with a history of thyroid cancer, multiple endocrine neoplasia, serious chronic conditions, or those who are pregnant or breastfeeding should speak with a specialist before exploring any option in this category. Self-assessment is not enough here.
The referral link below connects you to a third-party telehealth intake process. You are starting an eligibility check, not completing a purchase. Continuing is your choice at every step.
Affiliate disclosure: this is a referral link. We may earn a commission if you proceed through the intake at no extra cost to you.
This is not a direct sale. Not affiliated with Eli Lilly.
Retatrutide is a real investigational drug with a genuinely different mechanism, real clinical trial data, and serious pharmaceutical backing. It is not a supplement, not a miracle product, and not available as a standard retail purchase.
This site exists to explain that clearly. It is an independent editorial resource. It is not affiliated with Eli Lilly. It does not sell retatrutide. The referral link connects to a clinician-led telehealth intake process for people who want to explore whether they might qualify for supervised options.
If you are in the right situation, that intake path is worth understanding. If you are not, this page has given you enough to evaluate the next site you land on a lot more carefully.
What retatrutide is: An investigational once-weekly injectable drug being studied for weight management and metabolic health, targeting GLP-1, GIP, and glucagon receptors simultaneously. Developed by Eli Lilly. Currently in Phase 3 clinical trials.
Current status: Not FDA approved as of 2026. Not available as a standard retail product.
What this site offers: An independent educational review and telehealth intake referral. The affiliate link connects to a third-party clinician-led intake platform. This site does not sell retatrutide.
Who the referral path is for: People who want to explore whether they qualify for clinician-supervised weight management options and who understand that state eligibility may apply.
Non-affiliation notice: This website is not affiliated with Eli Lilly. It is not the official retatrutide website. Eli Lilly does not operate or endorse this page.